<DOC>
	<DOC>NCT01090310</DOC>
	<brief_summary>This extension study will assess the safety and efficacy of AIN457 versus placebo for maintaining uveitis suppression when reducing systemic immunosuppression</brief_summary>
	<brief_title>Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis</brief_title>
	<detailed_description />
	<mesh_term>Uveitis</mesh_term>
	<criteria>Patients who have completed the entire treatment period of the 24 week core study Inability or unwillingness to undergo repeated subcutaneous injections; inability to comply with study or followup procedures; any medical or psychiatric condition which, in the investigator's opinion wouldpreclude the participant from adhering to the protocol or completing the study per protocol. Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Quiescent uveitis</keyword>
	<keyword>intermediate uveitis</keyword>
	<keyword>panuveitis</keyword>
	<keyword>posterior uveitis</keyword>
	<keyword>uveitis</keyword>
	<keyword>NVS Definition: Words or phrases that best describe the protocol. Keywords help users find studies in the database.</keyword>
	<keyword>Avoid acronyms, abbreviations and trade names.</keyword>
	<keyword>Examples: Heart failure, aliskiren, heart attack, cardiovascular diseases</keyword>
	<keyword>Psoriasis, inflammatory skin disease, scaly patches</keyword>
</DOC>